NOVN.CH

130.88

+2.62%↑

LONN.CH

537.4

+1.09%↑

STMN.CH

92.8

-0.09%↓

NOVN.CH

130.88

+2.62%↑

LONN.CH

537.4

+1.09%↑

STMN.CH

92.8

-0.09%↓

NOVN.CH

130.88

+2.62%↑

LONN.CH

537.4

+1.09%↑

STMN.CH

92.8

-0.09%↓

NOVN.CH

130.88

+2.62%↑

LONN.CH

537.4

+1.09%↑

STMN.CH

92.8

-0.09%↓

NOVN.CH

130.88

+2.62%↑

LONN.CH

537.4

+1.09%↑

STMN.CH

92.8

-0.09%↓

Начало・Списък с акции・Roche Holding AG

Roche Holding AG

Затворен

СекторЗдравеопазване

378.6 2.55

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

373

Максимум

379

Ключови измерители
By Trading Economics
Приходи	1.8B 5.5B
Продажби	15B 31B
P/E Средно за сектора	23.748 108.767
Дивидентна доходност	2.59
Марж на печалбата	17.892
Служители	103,249
EBITDA	5.1B 12B

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	2.59% 2.21%

Пазарни показатели
By TradingEconomics
Пазарна капитализация	15B 303B
Предишно отваряне	376.05
Предишно затваряне	378.6

Настроения в новините

By Acuity

92%

6 / 352 Класиране в Healthcare

Roche Holding AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.01.2026 г., 10:07 ч. UTC

Печалби

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29.01.2026 г., 07:07 ч. UTC

Печалби

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

18.11.2025 г., 11:04 ч. UTC

Значими двигатели на пазара

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial

23.10.2025 г., 09:32 ч. UTC

Печалби

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23.10.2025 г., 05:54 ч. UTC

Печалби

Roche Raises Full-Year Earnings Outlook

29.01.2026 г., 11:40 ч. UTC

Пазарно говорене

Печалби

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29.01.2026 г., 06:05 ч. UTC

Печалби

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29.01.2026 г., 06:04 ч. UTC

Печалби

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29.01.2026 г., 06:03 ч. UTC

Печалби

Roche Issues 2026 View

29.01.2026 г., 06:02 ч. UTC

Печалби

Analysts Saw 2025 Core EPS at CHF19.70

29.01.2026 г., 06:02 ч. UTC

Печалби

Roche: 2025 Core EPS CHF19.46

29.01.2026 г., 06:01 ч. UTC

Печалби

Analysts Had Seen 2025 Sales At CHF61.47B

29.01.2026 г., 06:01 ч. UTC

Печалби

Roche 2025 Sales CHF61.52B

28.01.2026 г., 11:22 ч. UTC

Печалби

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

27.01.2026 г., 11:31 ч. UTC

Пазарно говорене

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

27.01.2026 г., 11:24 ч. UTC

Пазарно говорене

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

27.01.2026 г., 09:30 ч. UTC

Пазарно говорене

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

27.01.2026 г., 07:52 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Roche Obesity Study Data Look Encouraging -- Market Talk

16.01.2026 г., 17:03 ч. UTC

Пазарно говорене

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

12.01.2026 г., 14:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Pharma Sector Can Spend Big on M&A -- Market Talk

22.12.2025 г., 08:48 ч. UTC

Пазарно говорене

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

19.11.2025 г., 12:47 ч. UTC

Пазарно говорене

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

10.11.2025 г., 12:16 ч. UTC

Пазарно говорене

Печалби

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

23.10.2025 г., 09:19 ч. UTC

Пазарно говорене

Печалби

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23.10.2025 г., 09:11 ч. UTC

Пазарно говорене

Печалби

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23.10.2025 г., 05:09 ч. UTC

Печалби

Roche 3Q Sales Up 6% At CER

23.10.2025 г., 05:07 ч. UTC

Печалби

Roche 3Q Sales CHF14.92B

23.10.2025 г., 05:07 ч. UTC

Печалби

Analysts Had Seen 3Q Sales At CHF15.17B

23.10.2025 г., 05:07 ч. UTC

Печалби

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23.10.2025 г., 05:05 ч. UTC

Печалби

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

Сравнение с други в отрасъла

Ценова промяна

Roche Holding AG Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Roche Holding AG през последните 3 месеца.

Настроение

By Acuity

6 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.